See how top analysts and institutions rate NVO — including buy, hold, and sell recommendations.
| Rating Source | Action | Rating | Target Price | Updated |
|---|---|---|---|---|
| HSBC Securities | Upgrade | Hold → Buy | 2025-10-01 | |
| Morgan Stanley | Downgrade | Equal-Weight → Underweight | $47 | 2025-09-29 |
| Berenberg | Upgrade | Hold → Buy | 2025-09-17 | |
| Rothschild & Co Redburn | Upgrade | Neutral → Buy | 2025-09-16 | |
| Bernstein | Upgrade | Mkt Perform → Outperform | 2025-09-09 | |
| BNP Paribas Exane | Upgrade | Underperform → Neutral | $54 | 2025-08-13 |
| UBS | Downgrade | Buy → Neutral | 2025-08-05 | |
| HSBC Securities | Downgrade | Buy → Hold | $57 | 2025-07-31 |
| Barclays | Downgrade | Overweight → Equal Weight | 2025-07-30 |
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|
| November 2025 | 1 | 6 | 2 | 2 | 0 |
| October 2025 | 1 | 6 | 2 | 2 | 0 |
| September 2025 | 1 | 4 | 4 | 2 | 0 |
| August 2025 | 1 | 3 | 6 | 1 | 0 |
The majority of institutional investors have issued a "Buy" rating for NVO, and analyst sentiment aligns closely, with very few "Sell" recommendations. This suggests a broadly favorable outlook for the stock's performance.
